UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.